Session » Systemic Lupus Erythematosus – Clinical Aspects and Treatment II: Clinical Trial Design and Outcome Measures

Date: Monday, November 6, 2017

Time: 2:30PM-4:00PM

Meeting: 2017 ACR/ARHP Annual Meeting

2:30PM-4:00PM: Abstract Number: 1841

Can Systemic Lupus (SLE) Disease Activity be Consistently Scored and Interpreted with Simple, Rapid Outcome Measures?

2:30PM-4:00PM: Abstract Number: 1840

Comparison of Different Definitions of Remission in Systemic Lupus Erythematosus (SLE)– a Study Based on the BLISS-76 Clinical Trial

2:30PM-4:00PM: Abstract Number: 1839

Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials

2:30PM-4:00PM: Abstract Number: 1838

Estimating Duration of Response in Systemic Lupus Erythematosus (SLE) Trials

2:30PM-4:00PM: Abstract Number: 1843

Serum Albumin at 12 Months Post Biopsy Has Excellent Sensitivity and Specificity for Favorable 4 Year Renal Outcome in Lupus Nephritis (LN)

2:30PM-4:00PM: Abstract Number: 1842

Subsetting Systemic Lupus Erythematosus By Interferon Gene Signatures and Serologies (anti-dsDNA and Low Complement) Uncovers Significant Clinical Diversity

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].